Literature DB >> 15033918

Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells.

Teri L Wadsworth1, Julie M Carroll, Rebecca A Mallinson, Charles T Roberts, Charles E Roselli.   

Abstract

A common alternative therapy for benign prostatic hyperplasia (BPH) is the extract from the fruit of saw palmetto (SPE). BPH is caused by nonmalignant growth of epithelial and stromal elements of the prostate. IGF action is important for prostate growth and development, and changes in the IGF system have been documented in BPH tissues. The main signaling pathways activated by the binding of IGF-I to the IGF-I receptor (IGF-IR) are the ERK arm of the MAPK cascade and the phosphoinositol-3-kinase (PI3K)/protein kinase B (PKB/Akt) cascade. We tested the hypothesis that SPE suppresses growth and induces apoptosis in the P69 prostate epithelial cell line by inhibiting IGF-I signaling. Treatment with 150 microg/ml SPE for 24 h decreased IGF-I-induced proliferation of P69 cells and induced cleavage of the enzyme poly(ADP-ribose)polymerase (PARP), an index of apoptosis. Treatment of serum-starved P69 cells with 150 microg/ml SPE for 6 h reduced IGF-I-induced phosphorylation of Akt (assessed by Western blot) and Akt activity (assessed by an Akt kinase assay). Western blot analysis showed that SPE reduced IGF-I-induced phosphorylation of the adapter protein insulin receptor substrate-1 and decreased downstream effects of Akt activation, including increased cyclin D1 levels and phosphorylation of glycogen synthase kinase-3 and p70(s6k). There was no effect on IGF-I-induced phosphorylation of MAPK, IGF-IR, or Shc. Treatment of starved cells with SPE alone induced phosphorylation the proapoptotic protein JNK. SPE treatment may relieve symptoms of BPH, in part, by inhibiting specific components of the IGF-I signaling pathway and inducing JNK activation, thus mediating antiproliferative and proapoptotic effects on prostate epithelia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15033918     DOI: 10.1210/en.2003-1716

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3.

Authors:  F Strittmatter; S Walther; C Gratzke; J Göttinger; C Beckmann; A Roosen; B Schlenker; P Hedlund; K E Andersson; C G Stief; M Hennenberg
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 2.  Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia.

Authors:  Youngjoo Kwon
Journal:  Food Sci Biotechnol       Date:  2019-04-17       Impact factor: 2.391

3.  Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms--long-term follow-up of a placebo-controlled, double-blind, multicenter trial.

Authors:  Nikolai Lopatkin; Andrey Sivkov; Sandra Schläfke; Petra Funk; Alexander Medvedev; Udo Engelmann
Journal:  Int Urol Nephrol       Date:  2007-02-15       Impact factor: 2.370

Review 4.  Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction.

Authors:  Serap Gur; Philip J Kadowitz; Wayne J G Hellstrom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Saw palmetto and finasteride in the treatment of category-III prostatitis/chronic pelvic pain syndrome.

Authors:  Jennifer Yang; Alexis E Te
Journal:  Curr Urol Rep       Date:  2005-07       Impact factor: 2.862

6.  Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fibroblasts and c-Jun gene.

Authors:  Kai Wang; Song Jin; Dongdong Fan; Mingshuai Wang; Nianzeng Xing; Yinong Niu
Journal:  PLoS One       Date:  2017-02-14       Impact factor: 3.240

7.  Comparison between selected hormone and protein levels in serum and prostate tissue homogenates in men with benign prostatic hyperplasia and metabolic disorders.

Authors:  Katarzyna Grzesiak; Aleksandra Rył; Irena Baranowska-Bosiacka; Iwona Rotter; Barbara Dołęgowska; Marcin Słojewski; Olimpia Sipak-Szmigiel; Weronika Ratajczak; Anna Lubkowska; Emilia Metryka; Małgorzata Piasecka; Maria Laszczyńska
Journal:  Clin Interv Aging       Date:  2018-08-03       Impact factor: 4.458

8.  Potential Therapeutic Effects of Underground Parts of Kalanchoe gastonis-bonnieri on Benign Prostatic Hyperplasia.

Authors:  Antonio Palumbo; Livia Marques Casanova; Maria Fernanda Paresqui Corrêa; Nathalia Meireles Da Costa; Luiz Eurico Nasciutti; Sônia Soares Costa
Journal:  Evid Based Complement Alternat Med       Date:  2019-01-02       Impact factor: 2.629

9.  Metformin Attenuates Testosterone-Induced Prostatic Hyperplasia in Rats: A Pharmacological Perspective.

Authors:  Hala H Mosli; Ahmed Esmat; Reem T Atawia; Sherif M Shoieb; Hisham A Mosli; Ashraf B Abdel-Naim
Journal:  Sci Rep       Date:  2015-10-23       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.